The Analysis Guide adjusts the target price for CombiGene to SEK 21
2021 2020 2019 2018 2017 2016 2015 Here's how Thomas Nilsson writes in his latest analysis of CombiGene:As the company's epilepsy project CG01 enters phase 1/2 studies in 2022, we have recently raised the probability of launch to 15%. As the company enters...
read moreBioStock 27 august: CombiGene comments the international patent application
Interviews and presentations 2021 2021 2020 2019 2018 2017 2016 2015 The gene therapy company CombiGene announced yesterday that it has submitted a PCT application to protect the vectors developed within the lipodystrophy project CGT2. This application...
read moreCombiGene applies for international patent protection for the vectors developed within the CGT2 project
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene announces today that the company has submitted a so-called PCT application to protect the vectors being developed within the lipodystrophy project CGT2. The Patent Cooperation Treaty (PCT)...
read more28/8-1/9 Merab Kokaia speaks at The International Epilepsy Congress
Interviews and presentations 2021 2021 2020 2019 2018 2017 2016 2015 Professor Merab Kokaia, one of CombiGene's scientific founders, speaks at The International Epilepsy CongressThe 34th edition of The International Epilepsy Congress is held from 28 August...
read moreInterim Report January – June 2021
Financial reports 2021 2021 2020 2019 2018 2017 2016 2015 2014 2013 Interim Report January – June 2021>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...
read moreBiostock: CombiGene’s CEO on this summer’s news
2021 2020 2019 2018 2017 2016 2015 "The gene therapy company CombiGene ended July with two significant pieces of news. Firstly, the company has started GMP production of the drug candidate CG01 for the first clinical study that begin next year. Secondly,...
read morePatent approved in the U.S. and Russia for CombiGenes gene therapy candidate CG01
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene's gene therapy candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy, has received patent protection in the U.S., the world’s largest pharmaceutical...
read moreCombiGene initiates GMP production of CG01 for the first-in-human study
2021 2020 2019 2018 2017 2016 2015 CombiGene, in collaboration with its manufacturing partner, the leading AAV gene therapy contract manufacturer Viralgen, has today started GMP production of the drug candidate CG01, a gene therapy developed for the...
read moreArticle in BioStock: CombiGene announces several milestones for CG01
2021 2020 2019 2018 2017 2016 2015 Lund-based gene therapy company CombiGene continues to advance its main project CG01 ahead of the phase I studies scheduled to begin next year. The company is now ready for GMP production of drug substance and has also...
read moreCombiGene and Neurochase begin work to optimize the administration of CG01
2021 2020 2019 2018 2017 2016 2015 CombiGene's epilepsy project CG01 continues to advance towards the first clinical trial scheduled to begin in 2022. An important step on the way to clinical studies is optimizing the administration of CG01. CombiGene has...
read moreGMP plasmids released – Ready to start GMP production of CG01
2021 2020 2019 2018 2017 2016 2015 Cobra Biologics (Cobra), the gene therapy division of Cognate BioServices, a Charles River Laboratories International, Inc. company and CombiGene AB (publ) (CombiGene), the leading gene therapy company in the Nordic...
read moreOn June 8-10, CombiGene’s Preclinical Project Manager Annika Ericsson will participate in Next Generation Gene Therapy Vectors.
2021 2020 2019 2018 2017 2016 2015 ”I look forward to an exciting conference on the next generation of gene therapy vectors and to discuss limitations that current gene therapy vectors have, including immunogenicity, toxicity and safety”, says Annika....
read moreRecord date for reverse share split in CombiGene
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The Board of Directors of CombiGene AB (publ) ("CombiGene") has resolved that the record date for the reverse share split shall be 8 June. Through the reverse share split, twenty (20) existing shares...
read moreThe EU continues to invest in CombiGene
2021 2020 2019 2018 2017 2016 2015 This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> CombiGene’s epilepsy project CG01 has already been granted EUR 3.36 million by the EU programme Horizon 2020. Now the EU is...
read moreGunilla Lundmark new board member of CombiGene
News 2021 2021 2020 2019 2018 2017 2016 2015 At CombiGene’s Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions...
read moreFirst in human study within reach
News 2021 2021 2020 2019 2018 2017 2016 2015 This is an article from Ingeneious number 2 2021.Read the whole Ingeneious here >> A lot has happened at CombiGene during the first months of 2021 and when Ingeneious gets the opportunity to talk to...
read moreBulletin from the annual general meeting of CombiGene AB (publ)
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The following resolutions were passed at the annual general meeting (the “AGM”) of CombiGene AB (publ) (“CombiGene”) on 25 May 2021. Adoption of income statement and balance sheet and discharge from...
read moreCombiGene’s CEO Jan Nilsson is one of the speakers as “The Future of Swedish and Danish Life Science” celebrates its 10th anniversary
News 2021 2021 2020 2019 2018 2017 2016 2015 On September 2, Jan Nilsson will present his experiences within gene therapy under the heading Gene Therapy, an important tool for precision medicine.Here you will find information about the...
read moreIngeneious #2 2021, News from CombiGene
Ingeneious 2021 2021 2020 2019 2018 2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement...
read moreInterim Report January – March 2021
Financial reports 2021 2021 2020 2019 2018 2017 2016 2015 2014 2013 Interim Report January – March 2021 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life...
read moreBiostock summarizes CombiGene’s progress on the way to the first in human study
Interviews and presentations 2021 2021 2020 2019 2018 2017 2016 2015 Biostock summarizes CombiGene's progress on the way to the first in human study https://www.biostock.se/en/combigene-paved-the-way-for-2022-during-2020/ 2021 » News » Regulatory news...
read moreCombiGene annual report 2020
Financial reports 2021 2021 2020 2019 2018 2017 2016 2015 2014 2013 Annual report 2020>> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene...
read moreNotice of annual general meeting in CombiGene
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail. The shareholders of CombiGene AB (publ) are hereby summoned to...
read more30 april, CombiGene’s Karin Agerman is one of the hosts at ATMP world tour
News 2021 2021 2020 2019 2018 2017 2016 2015 On Friday April 30, CombiGene’s Chief Research & Development Officer Karin Agerman will host a discussion on manufacturing of gene therapies for pre-clinical and clinical studies at the ATMP world tour....
read moreArticel in BioStock: CombiGene raised 75MSEK through rights issue
News 2021 2021 2020 2019 2018 2017 2016 2015 This week, CombiGene announced the outcome of a rights issue, which was was resolved by the board of directors on 8 March 2021 based on the authorisation from the annual general meeting held on 29 June 2020....
read moreCombiGene announces outcome in rights issue
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...
read moreToday, CombiGene Celebrates the World Lipodystrophy Day
News 2021 2021 2020 2019 2018 2017 2016 2015 Currently, there is no cure for lipodystrophy, and just the secondary complications can be treated. Lipodystrophy is a rare and very serious disease. CombiGene continues to develop the pre-clinical work in the...
read moreCG01 project achieves important milestone, initiating preclinical biodistribution and toxicology studies
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene's epilepsy project CG01 is now advancing to the final phase of the preclinical program. Following the release of the material from the first large-scale production of CG01 on March 1,...
read moreCombiGene publishes EU Growth Prospectus relating to the rights issue
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 More information (in swedish) >> The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan,...
read moreThe board of directors of CombiGene resolves on a fully guaranteed rights issue of approximately SEK 75 million
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 The information in this press release is not intended for publication, public release or distribution, directly or indirectly, in or into the USA, Canada, Japan, Australia, Hong Kong, New Zealand,...
read moreRead about CombiGene’s latest progress and recruitment in Biostock
News 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene advances preclinically and recruits post-docThe interview >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under...
read moreWith the recruitment of Esbjörn Melin, CombiGene further strengthens the company’s scientific position
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene’s epilepsy project CG01 is in late preclinical phase and the company is currently intensifying preparations for the clinical program, where the Phase I study is scheduled to begin in 2022....
read moreThe material from the first large-scale production of CG01 is now released for use in the final parts of the preclinical program
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 In the autumn of 2020, CombiGene, together with the Spanish gene therapy manufacturer Viralgen, successfully completed the first large-scale production of the gene therapeutic drug candidate CG01,...
read moreCombiGene is preparing for the clinic, article in BioStock February 23
News 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene is preparing for the clinic, article in BioStock February 23 >> About CombiGene CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better...
read moreCombiGene’s lipodystrophy project receives EUR 882,500 in development funding from the EU Eurostar program
Regulatory news 2021 2021 2020 2019 2018 2017 2016 2015 CombiGene’s lipodystrophy project receives EUR 882,500 in development funding from the EU Eurostar program CombiGene is awarded EUR 481,000 in project grants and broadens cooperation in the...
read moreIngeneious #1 2021, News from CombiGene
Ingeneious 2021 2021 2020 2019 2018 2017 Read CombiGene´s newsletter Ingeneious in EnglishTo Ingeneious >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement...
read moreYear-end statement 2020
Financial reports 2020 2021 2020 2019 2018 2017 2016 2015 2014 2013 Year-end statement 2020 >> CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No...
read moreInterview in BioStock, CombiGene on the International Epilepsy Day and the pharmaceutical authorities’ positive response
News 2021 2021 2020 2019 2018 2017 2016 2015 Yesterday was International Epilepsy Day which aims to put the spotlight on a devastating disease caused by overactive nerve cells in the brain. According to WHO, epilepsy affects about 50 million people...
read moreCombiGene celebrates International Epilepsy Day
News 2021 2021 2020 2019 2018 2017 2016 2015 The International Epilepsy Day is held on the second Monday of February each year. There are 50 million people in the world living with epilepsy, of which 81,000 lives in Sweden. The purpose of International...
read moreResponse from the Swedish and UK Pharmaceutical Regulatory Authorities confirms CombiGene’s plan for CG01’s final preclinical studies
News 2021 2021 2020 2019 2018 2017 2016 2015 In December 2020, CombiGene held separate meetings with the Swedish Medicines Agency and its UK counterpart MHRA (Medicines & Healthcare products Regulatory Agency). The meetings took place after the two...
read moreCombiGene headhunts again
News 2021 2021 2020 2019 2018 2017 2016 2015 With experience from Medical Affairs at MERCK and early drug development at Karo Bio, a solid background in research from a doctoral thesis at Karolinska Institutet and postdoctoral research at Mount Sinai...
read moreWith the recruitment of Pernilla Fagergren, CombiGene strengthens the company further for the clinical studies in the epilepsy project CG01
News 2021 2021 2020 2019 2018 2017 2016 2015 In 2021, CombiGene's epilepsy project CG01 will focus on the final preclinical studies. In parallel, the company will intensify preparations for studies in humans, known as clinical studies, which are scheduled...
read moreBioStock interviews Martin Linhult, CombiGene’s new CMC expert
News 2021 2021 2020 2019 2018 2017 2016 2015 BioStock has spoken with the newly recruited CMC expert Martin Linhult who, with his long experience of bringing pharmaceuticals to the market, will primarily focus on the manufacturing process of CG01, which is...
read moreAbout CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.